Synergistic composition for potentiating stabilized ATP
Inventors
SAMANT, Rajaram • Tongra, Rajendra Prasad
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12208077-B2
Publication Date
2025-01-28
Expiration Date
Abstract
The present invention disclosed herein relates to a synergistic composition for potentiating stabilized ATP. Particularly, the invention provides the synergistic composition for improving cellular energy in a subject in need thereof. More particularly, the invention relates to compositions comprising synergistic combination therapeutically active ALCAR and MgAT which are present in the weight ratio of 1:0.002 to 1:1, along with pharmaceutically acceptable excipients. Further, the present composition is useful for improving tiredness, fatigue, cognition, memory, increase mental alertness, concentration, endurance, boost energy levels and wakefulness. It also useful for treating depression, anxiety related symptoms.
Core Innovation
The synergistic composition is configured for potentiating stabilized ATP and comprises a therapeutically active exogenous blend of acetyl L-carnitine and magnesium acetyl taurate together with pharmaceutically acceptable excipients. The acetyl L-carnitine and magnesium acetyl taurate are present in a weight ratio of 1:0.002 to 1:1, and the disclosed concept is that the two actives act together as an exogenous blend to potentiate stabilized ATP within a composition intended for therapeutic use.
The background problem is that ATP can be stabilized in a form such as Mg-ATP, but cellular energy can still be reduced, associated with tiredness and fatigue, weakness, and cognitive symptoms including memory and mental alertness. The patent addresses the need to improve cellular energy by potentiating stabilized ATP, including conditions associated with ATP depletion, and is framed in terms of treating or improving symptoms related to depression and anxiety.
The disclosed rationale connects acetyl L-carnitine with enhanced fatty-acid/acetyl-CoA metabolism, including the Krebs cycle and acetylcholine precursor, and connects magnesium acetyl taurate with increasing intracellular free Mg2+ to stabilize ATP as Mg-ATP complexes and to support mitochondrial function. Together, these mechanisms are presented as supporting mitochondrial function and cellular ATP levels, thereby improving endurance and energy-related and cognition-related outcomes.
Claims Coverage
The independent claim covers a synergistic pharmaceutical composition for potentiating stabilized ATP using an exogenous blend of acetyl L-carnitine and magnesium acetyl taurate with pharmaceutically acceptable excipients, with the actives present in a weight ratio of 1:0.002 to 1:1. The independent claim is further refined by multiple dependent claims that introduce quantitative composition constraints and functional outcomes following oral administration.
Exogenous acetyl L-carnitine and magnesium acetyl taurate blend for potentiating stabilized ATP
A synergistic composition for potentiating stabilized ATP comprising a therapeutically active exogenous blend consisting of acetyl L-carnitine and magnesium acetyl taurate, and pharmaceutically acceptable excipients.
Specified weight ratio range for the two actives
The acetyl L-carnitine and the magnesium acetyl taurate are present in a weight ratio of 1:0.002 to 1:1.
Acetyl L-carnitine content range
Acetyl L-carnitine is present in a range of 50% to 99% by a total weight of the composition.
Magnesium acetyl taurate content range
Magnesium acetyl taurate is present in a range of 1% to 50% by the total weight of the composition.
Pharmaceutically acceptable excipients with defined categories
Pharmaceutically acceptable excipients are selected from a group consisting of a diluent, binder, lubricant, glidant, additive, surfactant, stabilizer, antioxidant, and plasticizer, by total weight of the composition.
ATP level improvement with an effective unit dose
An administration of an effective unit dose improves ATP level by 65 to 575 folds over a normal cell control.
Oral administration to improve tiredness, fatigue, weakness, and cognition
Oral administration of the synergistic composition improves tiredness, fatigue, weakness, cognition, memory, mental alertness, concentration, endurance, energy levels, wakefulness, conditions associated with ATP depletion, depression, or anxiety related symptoms.
Overall, the claim coverage centers on a synergistic composition that uses an exogenous blend of acetyl L-carnitine and magnesium acetyl taurate with pharmaceutically acceptable excipients in a specified active weight ratio range to potentiate stabilized ATP, optionally further limited by active-content ranges, excipient categories, and functional outcomes including ATP level improvement and symptom improvements after oral administration.
Stated Advantages
Improves ATP level by 65 to 575 folds over a normal cell control.
Improves tiredness, fatigue, and weakness.
Improves cognition and memory.
Increases mental alertness and concentration.
Increases endurance and boosts energy levels.
Boosts wakefulness and improves conditions associated with ATP depletion.
Improves depression or anxiety related symptoms.
Documented Applications
Oral administration for improving tiredness, fatigue, weakness, cognition, memory, mental alertness, concentration, endurance, energy levels, wakefulness, and conditions associated with ATP depletion, including depression or anxiety related symptoms.
Interested in licensing this patent?